Anlotinib potentiates anti-PD1 immunotherapy via transferrin receptor-dependent CD8+ T-cell infiltration in hepatocellular carcinoma

Fei Song; Bo Hu; Xiao-Liang Liang; Jian-Wen Cheng; Cheng-Gui Wang; Peng-Xiang Wang; Tian-Lun Wang; Peng-Ju Tang; Hai-Xiang Sun; Wei Guo; Jian Zhou; Jia Fan; Zhong Chen; Xin-Rong Yang

doi:10.1002/ctm2.1738

Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (8) : e1738 DOI: 10.1002/ctm2.1738

RESEARCH ARTICLE

Anlotinib potentiates anti-PD1 immunotherapy via transferrin receptor-dependent CD8⁺ T-cell infiltration in hepatocellular carcinoma

Author information +

History +

PDF

Abstract

	•Synergistic effects of anlotinib and anti-PD-1 immunotherapy demonstrated in HCC preclinical models.
	•Anlotinib inhibits TFRC expression via the VEGFR2/AKT/HIF-1α pathway.
	•CXCL14 upregulation via TFRC suppression boosts CD8+ T-cell recruitment.
	•TFRC emerges as a potential biomarker for evaluating prognosis and predicting response to anti-PD-1-based therapies in advanced HCC patients.

Keywords

hepatocellular carcinoma / immune checkpoint blockade / transferrin receptor / tumour microenvironment / tyrosine kinase inhibitor

Cite this article

Download citation ▾

Fei Song,Bo Hu,Xiao-Liang Liang,Jian-Wen Cheng,Cheng-Gui Wang,Peng-Xiang Wang,Tian-Lun Wang,Peng-Ju Tang,Hai-Xiang Sun,Wei Guo,Jian Zhou,Jia Fan,Zhong Chen,Xin-Rong Yang. Anlotinib potentiates anti-PD1 immunotherapy via transferrin receptor-dependent CD8⁺ T-cell infiltration in hepatocellular carcinoma. Clinical and Translational Medicine, 2024, 14(8): e1738 DOI:10.1002/ctm2.1738

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.